http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112697912-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 |
| filingDate | 2020-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112697912-B |
| titleOfInvention | Method for detecting tofacitinib citrate intermediate and related impurities thereof |
| abstract | The invention belongs to the field of analytical chemistry, and particularly relates to a method for separating and determining tofacitinib citrate intermediate and related impurities thereof by an HPLC (high performance liquid chromatography) method, wherein an octadecylsilane chemically bonded silica is used as a filler in a chromatographic column, and a mobile phase A and a mobile phase B are adopted for gradient elution and enter a detector for detection; the mobile phase A is phosphate buffer solution-acetonitrile, and the mobile phase B is mixed solution of acetonitrile and methanol. The method can effectively separate the tofacitinib citrate intermediate and related impurities, has high sensitivity and separation degree, good repeatability and durability, simple operation and stable and reliable result, and has extremely important significance for realizing the tofacitinib citrate intermediate and the tofacitinib citrate quality control. |
| priorityDate | 2020-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.